Alcohol cirrhosis alters nuclear receptor and drug transporter expression in human livers

Drug Metabolism and Disposition

Volumn 41, Issue 5, 2013, Pages 1148-1155

  More, Vijay R ^a   Cheng, Qiuqiong ^a   Donepudi, Ajay C ^a   Buckley, David B ^b   Lu, Zhenqiang James ^c   Cherrington, Nathan J ^d   Slitt, Angela L ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b XenoTech LLC   (United States)

^c Arizona Statistical Consulting Laboratory   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCC1 PROTEIN; ABCC2 PROTEIN; ABCC3 PROTEIN; ABCC4 PROTEIN; ABCC5 PROTEIN; ABCC6 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CELL NUCLEUS RECEPTOR; FARNESOID X RECEPTOR; MESSENGER RNA; NUCLEAR FACTOR E2 RELATED FACTOR 2; ORGANIC ANION TRANSPORTER 2; PREGNANE X RECEPTOR; SLCO1B3 PROTEIN; SOLUTE CARRIER ORGANIC ANION 2B1 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALCOHOL LIVER CIRRHOSIS; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE STUDY; UPREGULATION;

CLUSTER ANALYSIS; GLUTATHIONE PEROXIDASE; HUMANS; INFLAMMATION MEDIATORS; LIVER; LIVER CIRRHOSIS, ALCOHOLIC; MEMBRANE TRANSPORT PROTEINS; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; PHARMACEUTICAL PREPARATIONS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 84876749483     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.049676     Document Type: Article

References (43)

1. Aleksunes LM, Campion SN, Goedken MJ, and Manautou JE (2008) Acquired resistance to acetaminophen hepatotoxicity is associated with induction of multidrug resistance-associated protein 4 (Mrp4) in proliferating hepatocytes. Toxicol Sci 104:261-273.
2. Aleksunes LM, Slitt AL, Maher JM, Dieter MZ, Knight TR, Goedken M, Cherrington NJ, Chan JY, Klaassen CD, and Manautou JE (2006) Nuclear factor-E2-related factor 2 expression in liver is critical for induction of NAD(P)H:quinone oxidoreductase 1 during cholestasis. Cell Stress Chaperones 11:356-363.
3. Aleksunes LM, Yeager RL, and Klaassen CD (2009) Application of multivariate statistical procedures to identify transcription factors that correlate with MRP2, 3, and 4 mRNA in adult human livers. Xenobiotica 39:514-522.
4. Anand BS (1999) Cirrhosis of liver. West J Med 171:110-115.
5. Baig NA, Herrine SK, and Rubin R (2001) Liver disease and diabetes mellitus. Clin Lab Med 21: 193-207.
6. Campion SN, Johnson R, Aleksunes LM, Goedken MJ, van Rooijen N, Scheffer GL, Cherrington NJ, and Manautou JE (2008) Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function. Am J Physiol Gastrointest Liver Physiol 295:G294-G304.
7. Chen Y, Song X, Valanejad L, Vasilenko A, More V, Qiu X, Chen W, Lai Y, Slitt A, and Stoner M,, et al. (2012) Bile salt export pump is dysregulated with altered farnesoid x receptor isoform expression in patients with hepatocellular carcinoma tissues. Hepatology DOI: 10.1002/ hep.26187.
8. Cheng Q, Aleksunes LM, Manautou JE, Cherrington NJ, Scheffer GL, Yamasaki H, and Slitt AL (2008) Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Mol Pharm 5:77-91.
9. Cheng X, Maher J, Dieter MZ, and Klaassen CD (2005) Regulation of mouse organic aniontransporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways. Drug Metab Dispos 33:1276-1282.
10. Doi N, Tomiyama Y, Kawase T, Nishina S, Yoshioka N, Hara Y, Yoshida K, Korenaga K, Korenaga M, and Moriya T, et al. (2011) Focal nodular hyperplasia-like nodule with reduced expression of organic anion transporter 1B3 in alcoholic liver cirrhosis. Intern Med 50: 1193-1199.
11. Elbekai RH, Korashy HM, and El-Kadi AO (2004) The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab 5:157-167.
12. Fuchs M (2012) Non-alcoholic fatty liver disease: The bile acid-activated farnesoid x receptor as an emerging treatment target. J Lipids 2012:934-396.
13. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, and Maldonado-Garza H (2009) Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 15:280-288.
14. Generaux GT, Bonomo FM, Johnson M, and Doan KM (2011) Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica 41:639-651.
15. Hardwick RN, Fisher CD, Canet MJ, Lake AD, and Cherrington NJ (2010) Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 38:2293-2301.
16. Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, and Cherrington NJ (2011) Variations in ATPbinding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos 39:2395-2402.
17. Hickman IJ and Macdonald GA (2007) Impact of diabetes on the severity of liver disease. Am J Med 120:829-834.
18. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, and Karlsson J (2007) Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 35:1333-1340.
19. Hoyert DL and Xu JQ (2012) Deaths: Preliminary data for 2011. National Vital Statistics Report 61:1-51.
20. Kim SJ and Kim DJ (2012) Alcoholism and diabetes mellitus. Diabetes Metab J 36:108-115.
21. Klaassen CD and Aleksunes LM (2010) Xenobiotic, bile acid, and cholesterol transporters: Function and regulation. Pharmacol Rev 62:1-96.
22. Klaassen CD and Slitt AL (2005) Regulation of hepatic transporters by xenobiotic receptors. Curr Drug Metab 6:309-328.
23. Lagas JS, Sparidans RW, Wagenaar E, Beijnen JH, and Schinkel AH (2010) Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATPbinding cassette efflux transporters. Mol Pharmacol 77:687-694.
24. Lieber CS, Jones DP, and Decarli LM (1965) Effects of prolonged ethanol intake: Production of fatty liver despite adequate diets. J Clin Invest 44:1009-1021.
25. Maher JM, Aleksunes LM, Dieter MZ, Tanaka Y, Peters JM, Manautou JE, and Klaassen CD (2008) Nrf2-and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol Sci 106:319-328.
26. Marek CJ, Tucker SJ, Konstantinou DK, Elrick LJ, Haefner D, Sigalas C, Murray GI, Goodwin B, and Wright MC (2005) Pregnenolone-16alpha-carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms. Biochem J 387:601-608.
27. More VR and Slitt AL (2011) Alteration of hepatic but not renal transporter expression in dietinduced obese mice. Drug Metab Dispos 39:992-999.
28. More VR, Wen X, Thomas PE, Aleksunes LM, and Slitt AL (2012) Severe diabetes and leptin resistance cause differential hepatic and renal transporter expression in mice. Comp Hepatol 11: 1 DOI: 10.1186/1476-5926-11-1.
29. Moriya N, Kataoka H, Fujino H, Nishikawa J, and Kugawa F (2012) Effect of lipopolysaccharide on the xenobiotic-induced expression and activity of hepatic cytochrome P450 in mice. Biol Pharm Bull 35:473-480.
30. Niemi M, Pasanen MK, and Neuvonen PJ (2011) Organic anion transporting polypeptide 1B1: A genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63:157-181.
31. Nishimura M and Naito S (2005) Tissue-specific mRNA expression profiles of human ATPbinding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 20: 452-477.
32. Nussler AK, Hao L, Knobeloch D, Yao P, Nussler NC, Wang Z, Liu L, and Ehnert S (2010) Protective role of HO-1 for alcohol-dependent liver damage. Dig Dis 28:792-798.
33. Ogasawara K, Terada T, Katsura T, Hatano E, Ikai I, Yamaoka Y, and Inui K (2010) Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab Pharmacokinet 25:190-199.
34. Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, and Staels B (2003) Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 17:259-272.
35. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, and Naveau S (2002) Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 35:635-638.
36. Slitt AL, Cherrington NJ, Maher JM, and Klaassen CD (2003) Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites. Drug Metab Dispos 31:1176-1186.
37. Svoboda M, Riha J, Wlcek K, Jaeger W, and Thalhammer T (2011) Organic anion transporting polypeptides (OATPs): Regulation of expression and function. Curr Drug Metab 12:139-153.
38. Syn WK, Teaberry V, Choi SS, and Diehl AM (2009) Similarities and differences in the pathogenesis of alcoholic and nonalcoholic steatohepatitis. Semin Liver Dis 29:200-210.
39. Teng S and Piquette-Miller M (2005) The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J Pharmacol Exp Ther 312:841-848.
40. Trauner M, Arrese M, Soroka CJ, Ananthanarayanan M, Koeppel TA, Schlosser SF, Suchy FJ, Keppler D, and Boyer JL (1997) The rat canalicular conjugate export pump (Mrp2) is downregulated in intrahepatic and obstructive cholestasis. Gastroenterology 113:255-264.
41. Treviño LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, and Pui CH, et al. (2009) Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 27:5972-5978.
42. Tsukamoto H, Towner SJ, Ciofalo LM, and French SW (1986) Ethanol-induced liver fibrosis in rats fed high fat diet. Hepatology 6:814-822.
43. Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, and Trauner M (2003) Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 38:717-727.